A new silver dressing, StopBac, used in the prevention of surgical site infections

Martin Oliverius1 | Jan Drozd1 | Petr Bratka2 | Adam Whitley1 | Beatrice Mohlenikova Duchonova3,4 | Robert Gürlich1

1Department of Surgery, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
2Faculty of Biomedical Engineering CTU in Prague, Kladno, Czech Republic
3Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic
4Department of Oncology and Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

Correspondence
Martin Oliverius, Assistant Professor, MD, PhD, FEBs, Srobarova 1150/50, Prague 10, 100 34 Czech Republic.
Email: martin.oliverius@gmail.com

Funding information
Ministry of Health of the Czech Republic, Grant/Award Number: 16-28375A

Abstract
Ideal dressings of surgical wounds should provide moist, semi-permeable, and antiseptic environments for optimal wound healing. To maximise patient comfort, surgical dressings must be hypoallergenic, not restrict movement, and allow patients to manage their personal hygiene. From the aspect of health care personnel, dressings should enable visual monitoring of the wound without the need for removing them, thus reducing the number of dressing changes. The active antimicrobial effect of silver cations has been demonstrated by many studies. StopBac is a unique surgical dressing based on the sol-gel process. Silver cations are bound in a colloidal solution in an organic-inorganic hybrid organosilicate oligomer. This gel is deposited on a pad using spray atomisation. The result is a polymer nanolayer matrix with prolonged and controlled release of silver ions. This pad forms part of a waterproof hypoallergenic transparent adhesive bandage. The goal of this study was to prospectively evaluate the ability of StopBac to prevent surgical site infections (SSIs) in patients after abdominal surgery. The secondary goal was to compare costs and determine the properties of this new material. A total of 32 patients were included in the study. The patients were followed up until their surgical wounds healed completely. An SSI occurred only in one patient.

1 INTRODUCTION

There is currently a wide range of dressings available for surgical wounds. At the Department of Surgery of University Hospital Kralovske Vinohrady, the standard dressing used after surgical procedures is a sterile gauze compress (Sterilkompres, Bastist Medical, CZE) with a non-transparent elastic film roll (Elastopore, Bastist Medical s.r.o. CZE).

The aim of this prospective observational study was to evaluate the effect of StopBac (Grade Medical, CZE), a new surgical dressing, in preventing surgical wound infections. StopBac consists of a matrix of organic-inorganic hybrid oligomers that ensure the controlled release of silver (Ag+) cations. The importance of silver ions in the treatment of chronic and especially infected wounds has been demonstrated in many studies.1-5
Under laboratory conditions, silver ions demonstrate high antimicrobial activity not only against bacteria but also against viruses and fungi. The antibacterial effect of the StopBac dressing, based on the controlled release of silver ions, is further enhanced locally by the high hydrophobicity of the hybrid polymer matrix layer, which creates an environment unsuitable for bacteria propagation. The aim of our study was to demonstrate the effect of this material in the prevention of surgical site infections (SSIs). Secondary aims were to report the total number of dressing changes per patient and the cost of the dressing.

2 | MATERIALS AND METHODS

From January to March 2020 at the Department of Surgery of University Hospital Kralovske Vinohrady, we used the StopBac dressing in 34 patients. Two patients were excluded from the study as they were transferred to other departments for part of their perioperative care. One had a massive pulmonary embolism, and the other developed coronavirus disease 2019. Both these patients were transferred to different departments where StopBac was not used. Thus, in total, 32 patients were included. These patients underwent hepatopancreatobiliary, colorectal, and hernia repair surgery, and they were prospectively followed for the duration of the study.

Patient medical histories were reviewed for the presence of any disease, which may impair wound healing, such as diabetes, ischaemic cardiac disease, hypertension, chronic lower limb ischaemia, chronic venous insufficiency, lipid metabolism disorders, and alcohol abuse (see Table 1). Furthermore, we noted whether patients were on anticoagulation therapy, had received neoadjuvant therapy, or had been taking antibiotics prior to the surgery. Another factor that can significantly influence wound healing is the nutritional status of the patient. All patients undergoing hepatopancreatobiliary surgery in our department undergo complex preoperative examination at the department of clinical physiology, as part of this examination, the nutritional status is assessed and when indicated preoperative nutritional support is given. The preoperative levels of total protein and albumin of the patient cohort are also reported in Table 1.

The patient cohort consisted of 19 females and 13 males. The average age was 66 years (median 67 years, range 50-84). Indications for surgery were pancreatic malignancy (n = 17), chronic pancreatitis (n = 1), hepatic cancer or liver metastases (n = 8), bile duct cancer (n = 1), kidney tumour (n = 1), and inguinal hernia (n = 3). Eleven patients underwent hemipancreatoduodenectomy (HPD), in one case this was combined with an extended right hepatectomy for bile duct cancer. One patient underwent total pancreatectomy, and one underwent an exploratory laparotomy. All these patients had undergone preoperative endoscopic retrograde cholangio pancreatography (ERCP) with drainage of the bile ducts. Two patients underwent distal pancreatectomy with splenectomy. Four patients with pancreatic cancer and inoperable findings underwent palliative gastroenteroanastomosis. Nine patients underwent liver resection (one combined with a HPD as mentioned above). One patient had a nephrectomy, and three patients underwent inguinal hernia repair.

3 | RESULTS

The average number of necessary wound dressing changes per patient was 1.8 (median 2; range 1-3). The first dressing change was performed on average 3.75 days after surgery (median 4, range 1-6). A second dressing change was performed on average 7 days after surgery (median 7, range 4-11). A third dressing change was required in only four patients, on average 9 days after surgery (median 8, range 7-13).

In accordance with the antibiotic guidelines in our hospital, all patients received ampicillin-sulbactam (1 g ampicillin, 0.5 g sulbactam) prophylactically 30 minutes before the start of surgery. A second dressing change was performed on average 7 days after surgery (median 7, range 4-11). A third dressing change was required in only four patients, on average 9 days after surgery (median 8, range 7-13).

Antibiotics were administered postoperatively in nine patients: in four patients for macroscopic signs of bile infection during surgery, in two patients for urinary tract infections, and in three patients for empyema of the gallbladder. The average duration of postoperative antibiotic therapy was 4.44 days (median 2, range 1-9).

Four patients had serum albumin levels below the normal range (Table 1), three of which also had low total protein. Two additional patients had isolated low total protein. All of these patients received nutritional preoperative support as
part of their preoperative preparation. No complications occurred in these patients. After hepatopancreatobiliary procedures, patients received complete parental nutrition; after HPD, this was combined with gradually increasing enteral nutrition given via a nasojejunal tube.

An SSI developed in only one patient. This patient underwent HPD for pancreatic cancer. A postoperative pancreatic fistula was detected on the third postoperative day, which drained into the surgical wound. The patient was treated with meropenem (Meronem; Pfizer s.r.o,

| TABLE 1 Patient characteristics |
| No | Age | Sex | Albumin (g/L) | Total protein (g/L) | Comorbidities | Diagnosis | Procedure | SSI |
|----|-----|-----|---------------|--------------------|---------------|------------|-----------|-----|
| 1  | 70  | F   | 65.2          | 42.2               | HY            | C250       | GEA       | No  |
| 2  | 66  | F   | 72.9          | 44.7               | DMII-T, MLG   | C250       | HPD       | SSI |
| 3  | 80  | F   | 65.6          | 43.3               | HY, CVD, MLG, AA | C250       | GEA       | No  |
| 4  | 60  | F   | 70.9          | 41.0               | HY, CVD, LMD, MLG | C250       | GEA       | Hematoma |
| 5  | 67  | F   | 80.5          | 39.8               | MLG, S, AA    | C250       | GEA       | No  |
| 6  | 68  | F   | 69.4          | 47.0               | HY, DMII-D, Y | C250       | HPD       | No  |
| 7  | 72  | M   | 62.4          | 40.9               | DMII-T, IHD, LMD, MLG, AA | C250       | HPD       | No  |
| 8  | 59  | M   | 67.5          | 33.8               | DMII-D, MLG, S, AA | C250       | TPE       | No  |
| 9  | 64  | M   | 69.2          | 46.2               | DMII-T, MLG, S, AA | C250       | HPD       | No  |
| 10 | 84  | F   | 68.2          | 43.2               | HY, DMII-T, PT, LMD, MLG | C250       | HPD       | No  |
| 11 | 56  | F   | 76.2          | 43.2               | CVD, PT, MLG, AA | C250       | HPD       | No  |
| 12 | 71  | M   | 66.7          | 43.6               | DMII-T, MLG, AA, NAC | C251       | DPE       | Hematoma |
| 13 | 58  | F   | 72.4          | 43.0               | LMD, MLG, S, AC | C251       | HPD       | No  |
| 14 | 62  | F   | 68.6          | 40.8               | HY, MLG, S, AA, NAC | C251       | DPE       | No  |
| 15 | 69  | F   | 58.3          | 31.8               | CVD, MLG, S, AA, NAC | C787       | LR        | No  |
| 16 | 68  | F   | 62.3          | 38.3               | HY, MLG, AA   | C787       | LR        | No  |
| 17 | 55  | F   | 70.2          | 46.8               | HY, MLG, AA, NAC | C787       | LR        | No  |
| 18 | 75  | F   | 67.5          | 43.7               | MLG, AA, NAC  | C787       | LR        | No  |
| 19 | 73  | M   | 69.8          | 40.0               | LMD, MLG, NAC | C787       | LR        | No  |
| 20 | 70  | M   | 65.1          | 38.2               | HY, IHD, CVD, LMD, MLG, AA | C220       | LR        | No  |
| 21 | 59  | F   | 71.1          | 42.8               | HY, MLG       | C220       | LR        | No  |
| 22 | 69  | M   | 56.9          | 35.6               | IHD, PT, MLG, S, AA, Y | C221       | LR        | Hematoma |
| 23 | 58  | F   | 72.7          | 47.5               | MLG, AA       | C240       | HPD       | No  |
| 24 | 50  | M   | 68.3          | 46.5               | HY, DMII-T, LMD, MLG, AA, AC | C241       | HPD       | No  |

Note: Normal range for whole protein level: 65 to 85 g/L; albumin level: 35 to 53 g/L. Abnormal values are highlighted in grey.

Abbreviations: AA, alcohol abuse; AC, anticoagulation therapy; CVD, chronic venous disease; DM II-D, diabetes mellitus treated with diet; DM II-T, diabetes mellitus type II treated with insulin; DM-I, diabetes mellitus type I; DPE, distal pancreatectomy with splenectomy; EL, explorative laparotomy; GEA, palliative gastroenteroanastomosis; HP, hernioplasty; HPD, hemipancreatoduodenectomy; HY, hypertension; ICD, International Classification of Diseases; IHD, ischaemic heart disease; LMD, lipid metabolism disorders; LR, liver resection; Miles, abdominoperineal amputation; MLG, malignant disease in previous medical history; NAC, neoadjuvant chemotherapy; NE, nephrectomy; PT, phlebothrombosis; S, smoking; SSI, surgical site infection; TP, total pancreatectomy.
CZE) at a dose of 4 g per 24 hours four from the third to tenth postoperative day. A fluid collection was drained under computed tomography guidance on the seventh postoperative day. Microbial cultures revealed the presence of *Escherichia coli* and *Enterococcus faecium*. On the 30th postoperative day, the drain was removed and the fistula was considered healed. The patient underwent daily wound irrigation using Prontosan Wound Irrigation Solution (B. Braun Medical AG, CH) and daily changes of sterile dressings until the twelfth postoperative day. The surgical wound healed completely on the 16th postoperative day.

Three patients developed subcutaneous haematoma in the surgical wound. One of these patients was taking nadroparin (Fraxiparine 9500 IU/1 mL; Aspen Pharma Trading Limited, IRL) in the perioperative period at a dose of 0.6 mL every 12 hours due to atrial fibrillation. Another had received neoadjuvant chemoradiotherapy consisting of three doses of gemcitabine, 36 greys of radiation therapy in 15 fractions followed by five series of FOLFIRINOX. One patient developed a seroma in the perineal wound after rectal amputation, which was drained during an outpatient visit. No other wound complications occurred in the remaining 22 patients.

In most patients following major surgery (pancreas, liver, or colorectal resections) with a surgical wound length of 30 ± 5 cm (bilateral subcostal incision or extended midline incision), an average of 1.8 dressings were applied (median 2; range 1-3) using StopBac STERILE (10 × 30 cm and 10 × 10 cm over each other). The first dressing change took place at an average of 3.8 days after surgery (median 4; range 1-6) and the second on the seventh postoperative day (median 7; range 4-11). The wound was inspected during each dressing change, and if it was clean and dry without signs of inflammation or retention, it was dressed using only OpSite spray (Smith & Nephew Consumer, GB). Four patients required three dressing changes using StopBac STERILE on the ninth postoperative day on average (median 8; range 7-15) because of mild serous and in one case sanguineous discharge. As mentioned previously, in one patient who developed a pancreatic leak and subsequently an SSI, the wound was treated by regular irrigation and covered with sterile gauze from the second dressing change (third postoperative day) onwards.

Standard procedure at our department calls for wound dressings to be changed on the first or second postoperative day, depending on their appearance and subsequently on the third to fifth and seventh postoperative days. After this, if there are no complications and the wound is healing by primary intention, the wound is covered by only the OpSite spray until the sutures are removed. In our department, the standard material used on the first to third wound dressings are the sterile compress Sterilkompres (Batist Medical, CZE) and the adhesive tape Elastopore (Batist Medical, CZE). If the wound does not show any signs of SSI and is healing by primary intention on the second or third dressing change, it is covered using only the Elastopore adhesive pad (Batist Medical, CZE).

Overall, the cost of dressing a surgical wound in the hepatopancreatobiliary area per patient using StopBac STERILE if one to two dressing changes are needed ranges from CZK 110 to 164 (EUR 4.04-6.03 or USD 4.80-7.15). The cost using the classical form of wound dressings (two to three dressing changes using two packages of sterile compresses and one dressing change using Elastopore adhesive tape per dressing change) ranges from CZK 142 to 213 (EUR 5.23-7.83 or USD 6.19-9.29)—based on the exchange rate on October 25, 2020, of EUR/CZK 27.21 and USD/CZK 22.94. Moreover, these costs do not include a calculation of the work performed by the nursing staff, the disinfectant swabs and instruments used, or the decreased need for analgesics during dressing changes.

**DISCUSSION**

The composite material of the StopBac pad ensures efficient drainage of exudate into the absorbent layer, which is separated from the wound by a specifically perforated film, thus preventing the exudate from leaking back into

---

**FIGURE 1** StopBac left on a wound until planned wound dressing. A serosanguineous exudate is seen seeping through the dressing.
the wound. The surface of the pad’s outer layer is covered by a nanolayer consisting of an organic-inorganic hybrid oligomer matrix with a high degree of conversion that ensures the controlled release of silver ions (antibacterial effect). At the same time, given its hydrophobic properties, it minimises the risk of the dressing adhering to the wound.

The StopBac material creates an environment suitable for healing, where undesired microbial contamination is at the same time controlled thanks to the prolonged release of silver ions. If used correctly, dressings that use silver as an antimicrobial agent are suitable for dressing wounds with bacterial infection. Silver ions have been demonstrated to have an inhibitory effect against both gram-positive and gram-negative bacterial strains. The antibacterial effect of silver ions is also due to their high potential for interrupting the transport and release of potassium ions (K+) from bacterial cells and blocking the synthesis of adenosine triphosphate. Moreover, the ions of silver easily bind to a whole range of biomolecules such as DNA, RNA, and peptides, forming insoluble compounds and thus preventing bacterial cell division and reproduction. Hybrid nanolayers prepared using the sol-gel method based on 3-trimethoxy-silyl propylmethacrylate containing ion-bound silver cations introduced in the form of a solution of silver nitrate, demonstrate high antibacterial effects, and are suitable for medical applications.

Our prospective observational study focused primarily on postoperative surgical wounds that were aseptic (hernia surgery) and potentially contaminated (hepatopancreatobilary and colorectal surgery and nephrectomy). It is a well-known fact that ERCP with stent implantation prior to surgery significantly increases the risk of intra-abdominal infection and wound contamination. However, in our study, neither ERCP nor any other known risk factors affected the development of SSI. Twenty-eight patients underwent surgery for a malignancy, seven of which had neoadjuvant chemotherapy.

It is a well-documented fact that preoperative nutritive status significantly influences healing after gastrointestinal surgery, and for this reason, patients undergoing major abdominal procedures in our institution undergo nutritional screening as part of the preoperative preparation. In our cohort, the one patient who developed an SSI had serum values of total protein and albumin within the normal range for our laboratory (72.9 and 44.7 g/L, respectively).

In contrast to other studies that used silver in their dressings, we did not focus on its effect on wound healing but rather on its role in the prevention of SSI development. In this study, if the dressing did not show signs of loss of integrity or seepage outside its margins. It was

FIGURE 2  Wound appearance after StopBac dressing saturated with wound secretion is removed (the text on a dressing marks the day of planned removal)
kept on the wound until the planned dressing change on the third or fourth postoperative day. The dressing was not removed even if it was bloody or saturated with secretions (see Figures 1 and 2). This was fundamentally different from our routine practice, where the gauze dressing is changed at any time if blood or secretions are seen.

With regard to the focus of our department being hepatopancreatobiliary surgery, the majority of the patients included this study (18 patients) underwent pancreatic procedures, 11 of which were hemipancreatoduodenectomies, in one case combined with an extended hepatectomy. It is necessary to bear in mind that the complications of these, the most common being pancreatic leak, can significantly complicate healing of the surgical wound. A pancreatic fistula occurred in one patient in our cohort. The fistula drained through the surgical wound, as a consequence this led to a wound infection and healing via secondary intention. Our team plan to follow this study with a larger multicentre study where the pancreatic procedures will be analysed as a unique cohort.

In total, only one SSI occurred in our cohort of 32 patients (3.12%). In the year 2019, a total of 1935 operations were performed in our department. SSIs occurred in 86 (4.4%) of these patients. Hepatopancreatobiliary procedures constituted 168 of these operations, from them 19 patients (11.3%) developed SSIs. Published data from large hepatobiliary surgery centres report SSIs in HPB surgery to range from 18% to 29%.14,15

The lower prevalence of SSIs in our cohort may be explained by the preoperative preparation of these patients, which includes nutritative interventions and prehabilitation. Nonetheless, an accurate comparison is not possible with a small patient cohort and observational study design.

From the patient's perspective smaller, elastic and thin dressings facilitate mobilisation and are more comfortable. StopBac is water repellent on its superficial surface, which dressing enables patients to more easily manage their personal hygiene earlier after surgery. We did not record any allergic reactions, reddening or skin irritation. Another benefit of using the StopBac dressing was the overall reduction in the number of dressing changes. This increases patient comfort by decreasing the number of dressing changes needed and ensuring early patient mobilisation and proper personal hygiene.

ACKNOWLEDGEMENTS
The authors would like to thank GRADE MEDICAL Ltd, CZ for providing the material used in this study.

CONFLICT OF INTEREST
This study used material provided free of charge by GRADE MEDICAL Ltd, Ing. Petr Bratka works for GRADE MEDICAL Ltd, CZ.

DATA AVAILABILITY STATEMENT
Data available on request due to privacy/ethical restrictions

ORCID
Martin Oliverius https://orcid.org/0000-0002-8649-3824
Petr Bratka https://orcid.org/0000-0002-9276-7529

REFERENCES
1. Woodmansey EJ, Roberts CD. Appropriate use of dressings containing nanocrystalline silver to support antimicrobial stewardship in wounds. Int Wound J. 2018;15(6):1025-1032. https://doi.org/10.1111/iwj.12969.
2. Cooper R, Kirketerp-Moller K. Non-antibiotic antimicrobial interventions and antimicrobial stewardship in wound care. J Wound Care. 2018;27(6):355-377. https://doi.org/10.12968/jowc.2018.27.6.355.
3. Dissemond J, Bottrich JG, Braunwarth H, Hilt J, Wilken P, Munter KC. Evidence for silver in wound care—meta-analysis of clinical studies from 2000-2015. J Disch Dermatol Ges. 2017; 15(5):524-535. https://doi.org/10.1111/ddg.13233.
4. Li HZ, Zhang L, Chen JX, Zheng Y, Zhu XN. Silver-containing dressing for surgical site infection in clean and clean-contaminated operations: a systematic review and meta-analysis of randomized controlled trials. J Surg Res. 2017;215:98-107. https://doi.org/10.1016/j.jss.2017.03.040.

5. Walker M, Parsons D. The biological fate of silver ions following the use of silver-containing wound care products—a review. Int Wound J. 2014;11(5):496-504. https://doi.org/10.1111/j.1742-481X.2012.01115.x.

6. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999;12(1):147-179.

7. Slamborova I, Zajicova V, Karpiskova J, Exnar P, Stibor I. New type of protective hybrid and nanocomposite hybrid coatings containing silver and copper with an excellent antibacterial effect especially against MRSA. Korean J Couns Psychother. 2013;33(1):265-273. https://doi.org/10.1016/j.msec.2012.08.039.

8. Abbaszadegan A, Gholami A, Abbaszadegan S, et al. The effects of different ionic liquid coatings and the length of alkyl chain on antimicrobial and cytotoxic properties of silver nanoparticles. Iran Endod J. 2017;12(4):481-487. https://doi.org/10.22037/iej.v12i4.17905.

9. Yamanaka M, Hara K, Kudo J. Bactericidal actions of a silver ion solution on Escherichia coli, studied by energy-filtering transmission electron microscopy and proteomic analysis. Appl Environ Microbiol. 2005;71(11):7589-7593. https://doi.org/10.1128/AEM.71.11.7589-7593.2005.

10. Lopez-Cardallo G, Higuera L, Gavara R, Hernandez-Munoz P. Silver ions release from antibacterial chitosan films containing in situ generated silver nanoparticles. J Agric Food Chem. 2013;61(1):260-267. https://doi.org/10.1021/jf304006y.

11. Fang Y, Gurusamy KS, Wang Q, et al. Meta-analysis of randomized clinical trials on safety and efficacy of biliary drainage before surgery for obstructive jaundice. Br J Surg. 2013;100(12):1589-1596. https://doi.org/10.1002/bjs.9260.

12. Wu JM, Ho TW, Yen HH, et al. Endoscopic retrograde biliary drainage causes intra-abdominal abscess in pancreaticoduodenectomy patients: an important but neglected risk factor. Ann Surg Oncol. 2019;26(4):1086-1092. https://doi.org/10.1245/s10434-019-07189-y.

13. Hennessy DB, Burke JP, Ni-Dhonochu T, Shields C, Winter DC, Mealy K. Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multiinstitutional study. Ann Surg. 2010;252(2):325-329. https://doi.org/10.1097/SLA.0b013e3181e9819a.

14. Ceppa EP, Pitt HA, House MG, et al. Reducing surgical site infections in hepatopancreatobiliary surgery. HPB (Oxford). 2013;15(5):384-391. https://doi.org/10.1111/j.1477-2574.2012.00604.x.

15. Takahashi Y, Takesue Y, Fujiwara M, et al. Risk factors for surgical site infection after major hepatobiliary and pancreatic surgery. J Infect Chemother. 2018;24(9):739-743. https://doi.org/10.1016/j.jiac.2018.05.007.

16. Leaper D. Appropriate use of silver dressings in wounds: international consensus document. Int Wound J. 2012;9(5):461-464. https://doi.org/10.1111/j.1742-481X.2012.01091.x.

How to cite this article: Oliverius M, Drozd J, Bratka P, Whitley A, Mohlenikova Duchonova B, Gürlie R. A new silver dressing, StopBac, used in the prevention of surgical site infections. Int Wound J. 2021;1–7. https://doi.org/10.1111/iwj.13593